Beida pharmaceutical bpi-23314 drug clinical trial application accepted

On January 3, Beida pharmaceutical announced that it had received the acceptance notice (acceptance No.: cxhl1900001, cxhl1900002 and cxhl1900003) issued by the State Drug Administration, and the application for clinical trials of bpi-23314 and bpi-23314 tablets (hereinafter referred to as "the clinical trial") declared by Beida pharmaceutical had been accepted by the State Drug administration Bpi-23314 is a new molecular entity compound independently developed by Beida Pharmaceutical Co., Ltd with independent intellectual property rights It is a strong and highly selective bromine domain and extra terminal domain, Bet) oral small molecule inhibitors can specifically inhibit the function of bet family proteins, regulate the transcription and expression of cancer-related genes, and then affect cell growth, proliferation, apoptosis and other physiological processes, and finally achieve the goal of inhibiting tumor growth The abnormal expression and dysfunction of bet protein are associated with various diseases As a potential anti-tumor target, it has been widely concerned and developed in recent years As of the disclosure date of this announcement, the drugs targeted by BET are in the early clinical stage, and there is no drug on the market at home and abroad According to the announcement of the work plan for the reform of chemical drug registration and classification issued by the State Food and Drug Administration (No 51 in 2016), bpi-23314 belongs to the category of "innovative drugs not listed at home and abroad", and its registration is classified as category 1 chemicals The following is the full text of the announcement: